Service de Gynécologie, HFME, Hospices Civils de Lyon
Bron, 69500, France
NCT Number: NCT05741580
There are currently different treatment options in the management of stress urinary incontinence according to the latest recommendations. Suburethral slings are currently considered the first surgical option due to an excellent cure rate of around 90%. Nevertheless, due to a risk of prosthetic complications and numerous current controversies over the placement of synthetic tissue, other therapeutic alternatives must be offered to patients.
Peri-urethral bulk agent injections have been used since 2006 in urinary incontinence and should be integrated into the therapeutic arsenal. This is a minimally invasive technique performed under local anesthesia on an outpatient basis. The mechanism of action is explained by better coaptation of the urethra and increased resistance to urine flow during the bladder filling phase. It also increases the strength of the striated sphincter thanks to a better arrangement of muscle fibers.
According to the European Association of Urology (EAU), the use of bulk agents is recommended for the management of urinary incontinence in elderly and/or frail patients whose comorbidities contraindicate surgical management. These peri-urethral injections can also be offered to patients with incontinence due to sphincter deficiency but also to young women with stress urinary incontinence who are ready to accept a partial improvement in their incontinence. The personal choice of the patient is currently a decisive factor for the implementation of a treatment for functional disorders and in particular for urinary incontinence.
Looking for future studies?
Notify Me18 year and older
Female
Observational
Bron, 69500, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
percentage of patients with improvement in their symptoms
Time frame: at 7 days after surgery
percentage of patients with improvement in their symptoms on the PGI-I scale (score 1, 2, or 3)
Hospices Civils de Lyon
Other
Evolution of Symptoms After Peri-urethral Bulk Agent Injection of Bulkamid® for Urinary Incontinence
Acronym: BULKIU
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07070063
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Wroclaw, Lower Silesian Voivodeship, Poland
View Trial DetailsNCT07689409
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Izmir, İzmir, Turkey (Türkiye)
View Trial DetailsNCT05443074
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Ribeirão Preto, São Paulo, Brazil
View Trial DetailsNCT05880862
Accidental Falls, Female Urogenital Diseases
Galveston, Texas, United States
View Trial Details